Who are Placebo to V920's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TEP, Tat, Mycobacterium Vaccae for Injection, HD Vaccine, Cervavac as three dose regimen, GamTBvac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-v920.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to V920 — Competitive Intelligence Brief

Placebo to V920 (Placebo to V920) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic vaccine. Area: Oncology / Immunology.

phase 3 Therapeutic vaccine Human papillomavirus (HPV) antigens Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Placebo to V920 (Placebo to V920) — Merck Sharp & Dohme LLC. V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to V920 TARGET	Placebo to V920	Merck Sharp & Dohme LLC	phase 3	Therapeutic vaccine	Human papillomavirus (HPV) antigens
TEP	TEP	Immungenetics AG	marketed	Therapeutic vaccine
Tat	Tat	Barbara Ensoli, MD	marketed	Therapeutic vaccine	HIV Tat protein
Mycobacterium Vaccae for Injection	Mycobacterium Vaccae for Injection	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	marketed	Immunotherapeutic vaccine
HD Vaccine	HD Vaccine	Insight Therapeutics, LLC	marketed	Therapeutic vaccine	Huntingtin protein (HTT)
Cervavac as three dose regimen	Cervavac as three dose regimen	Serum Institute of India Pvt. Ltd.	phase 3	Therapeutic vaccine	HPV16 and HPV18 antigens
GamTBvac	GamTBvac	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	phase 3	Therapeutic vaccine	Mycobacterium tuberculosis antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic vaccine class)

Immunitor LLC · 3 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Henogen · 2 drugs in this class
SK Chemicals Co., Ltd. · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Cytos Biotechnology AG · 2 drugs in this class
Clinical Research Organization, Dhaka, Bangladesh · 1 drug in this class
Barbara Ensoli, MD · 1 drug in this class
Green Cross Corporation · 1 drug in this class
Chiang Mai University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to V920 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-v920. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab